Removal of access to alemtuzumab for patients with aggressive multiple sclerosis

被引：1
|
作者：
Thompson, Alan J. [1 ]
Giovannoni, Gavin [2 ]
机构：
[1] UCL, UCL Inst Neurol, London WC1N 3BG, England
[2] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2013年 / 346卷
关键词：
CONTROLLED PHASE-3 TRIAL;
D O I：
10.1136/bmj.f275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
    Karly P. Garnock-Jones
    Drugs, 2014, 74 : 489 - 504
  • [42] Alemtuzumab Induces Unexplored Cardiac Effects in Multiple Sclerosis Patients
    Brambilla, Laura
    Zecca, Chiara
    Perugini, Jacopo
    Pareja, Lorena
    Barbic, Franca
    Camera, Giorgia
    Riva, Stefania
    Antozzi, Carlo
    Gobbi, Claudio
    Brenna, Greta
    Furlan, Raffaello
    Mantegazza, Renato
    Rossi, Silvia
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 42 - 43
  • [43] Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
    Rauma, Ilkka
    Mustonen, Tiina
    Seppa, Juha Matti
    Ukkonen, Maritta
    Mannikko, Marianne
    Verkkoniemi-Ahola, Auli
    Kartau, Marge
    Saarinen, Jukka T.
    Luostarinen, Liisa
    Simula, Sakari
    Ryytty, Mervi
    Ahmasalo, Riitta
    Sipila, Jussi O. T.
    Pieninkeroinen, Ilkka
    Tapiola, Tero
    Remes, Anne M.
    Kuusisto, Hanna
    JOURNAL OF NEUROLOGY, 2022, 269 (02) : 824 - 835
  • [44] Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
    Buonomo, Antonio Riccardo
    Zappulo, Emanuela
    Viceconte, Giulio
    Scotto, Riccardo
    Borgia, Guglielmo
    Gentile, Ivan
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 709 - 717
  • [45] Real clinical experience with alemtuzumab in patients with multiple sclerosis in Slovakia
    Kantorova, E.
    Martinikova, M.
    Kianickova, M.
    Vitkova, M.
    Vitkova, M.
    Kovacova, S.
    Mako, M.
    Hancinova, V.
    Lisy, L.
    Koleda, P.
    Rohalova, J.
    Poloniova, J.
    Karlik, M.
    Slezakova, D.
    Klimova, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 537 - 537
  • [46] Comparison of Two Treatment Schedules with Alemtuzumab in Patients with Multiple Sclerosis
    von Wussow, Peter
    Schreiber, Martin
    NEUROLOGY, 2016, 86
  • [47] Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis
    Masuda, Hiroki
    Mori, Masahiro
    Kuwabara, Satoshi
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (12): : 1251 - 1251
  • [48] Cardiovascular monitoring during alemtuzumab infusion in multiple sclerosis patients
    Giossi, R.
    Roldan, E. Tomas
    Costanza, M.
    Antozzi, C.
    Frangiamore, R.
    Clerici, V. Torri
    Confalonieri, P.
    Tozzo, A.
    Mantegazza, R.
    Brambilla, L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 267 - 268
  • [49] Safety and efficacy of IV cladribine versus alemtuzumab in aggressive multiple sclerosis: a retrospective cohort study
    Bose, Gauruv
    Freedman, Mark
    Rush, Carolina
    Bowman, Marjorie
    Atkins, Harold
    NEUROLOGY, 2018, 90
  • [50] Aggressive multiple sclerosis
    Menon, S.
    Morrow, S. A.
    Kremenchutzky, M.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 169 - 169
12345